Filing Flows › 8-K events › Accendra Health
Accendra Health: entry into a material definitive agreement
Form 8-K filed Nov 2, 2026 · items 1.01, 7.01
Entry into a material definitive agreementAccendra Health Announces Extension of $150 Million Receivables Sale Program To 2029
What the filing says
On October 29, 2026, Accendra Funding LLC (“Accendra Funding”) and Byram Healthcare Centers, Inc. (“Byram”) each a wholly-owned subsidiary of Accendra Health, Inc., entered into the Third Amendment to the Amended & Restated Receivables Purchase Agreement (the “RPA Amendment”), which amends that certain Amended & Restat
ScaleThe filing names $150.0M: about 6% of Accendra Health's annual revenue ($2.41B, four times the latest quarter).
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
Accendra Health at a glance
Accendra Health, Q3 2026: revenue $602M (-14% year over year), operating margin 0.2%. The chart follows the revenue to costs, profit and cash.
Accendra Health: every quarter, Q/Q and Y/Y, holders and guidance →
Accendra Health’s other material 8-Ks
- Nov 3, 2026 — CEO changes
- Oct 30, 2026 — Delisting notices Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.